FindDrugs.org

SkinnyRx Review

Brand-level review · Last reviewed Sep 24, 2026

5.59/10

Operator-trust score

The brand-level factors every category shares — legitimacy, clinical oversight, transparency, privacy, policy, support — not price or per-treatment value.

Clinician accessCash-pay

Our verdict

SkinnyRx is the consumer brand of Lean Rx, Inc. of Sacramento, California, a telehealth platform selling compounded semaglutide and tirzepatide in injectable, sublingual and tablet forms through asynchronous in-app care with no scheduled appointment. Its operator-trust score is 5.59 — the brand-level factors every category shares, not price or per-treatment value. It publishes an unusual amount on its own site for this category: cancellation and refund terms in full, per-lot quality-control standards against named USP references, per-product dosing guides, and a named medical director. It does not name the pharmacy that compounds its medication on its site — confirmed absent on the rendered pages; the one identified publicly surfaced through a class-action filing. A February 2026 FDA warning letter for false or misleading marketing is on the record.

SkinnyRx plans & reviews by category

Each category is scored separately. Read the full review where one exists — or check current pricing directly.

Weight Loss / GLP-1

5.68/10
Read the Weight Loss / GLP-1 reviewCheck price
  • Semaglutide · injectionStarting price published on the brand's own pages; standard-dose pricing is not published — confirmed absent on the rendered pricing pages searched 2026-08-24.
  • Semaglutide · sublingualStarting price published on the brand's own pages; standard-dose pricing is not published — confirmed absent on the rendered pricing pages searched 2026-08-24.
  • Tirzepatide · injectionStarting price published on the brand's own pages; standard-dose pricing is not published — confirmed absent on the rendered pricing pages searched 2026-08-24.
  • Tirzepatide · oralStarting price published on the brand's own pages; standard-dose pricing is not published — confirmed absent on the rendered pricing pages searched 2026-08-24.

Prices as of Sep 24, 2026 — verify current on the brand's site.

Key takeaways

  • Publishes its cancellation and refund policy in full on its own FAQ, including a full refund any time before the prescription review completes and no charge at all if the provider finds the patient ineligible.
  • Its terms impose binding individual arbitration with a class-action and jury-trial waiver, a one-year limit to file and a 30-day written opt-out: clarity is a genuine strength here, fairness is mixed.
  • Publishes per-lot quality-control disclosure against named standards — potency within plus or minus 10% of labelled concentration, sterility to USP 797.1 tested every batch, a pH test, and bacterial endotoxin limits to USP 85.
  • It names no dispensing pharmacy on its site — confirmed absent on the rendered pages, which refer only to "our partner pharmacies", "503A pharmacies" and "a partner pharmacy"; the one identified publicly, Foothills Professional Pharmacy, surfaced through a class-action filing.
  • An FDA warning letter (#717989, 2026-02-20) to Lean Rx, Inc. dba Skinny Rx cites false or misleading marketing of compounded GLP-1 products.
  • A putative class action, Buchholz v. Lean Rx, Inc., No. 5:26-cv-00846 (N.D. Cal., filed 2026-01-26), alleges improper compounding and inadequate medical evaluation. The allegations are untested and no court has made findings.
  • Its BBB profile carries 144 complaints with refund and cancellation handling as the dominant theme, at a B rating and not accredited.
  • Its privacy policy states it does NOT honour Do Not Track signals, and the site discloses using hashed, de-identified customer data to build custom audiences for targeted advertising on Facebook, Google and similar platforms — both read from the brand’s own pages rather than inferred.

What is SkinnyRx?

SkinnyRx is operated by Lean Rx, Inc., a telehealth company in Sacramento, California. It dispenses compounded GLP-1 medication through state-licensed pharmacies that compound to individual prescriptions and handles care asynchronously through an app rather than scheduled video visits; the states it serves are not published on its site, and compounded medications are not FDA-approved. A medical director is identified on its product pages, and its providers are described as US-based, licensed and board certified, though no individual prescribing clinician is identified — confirmed absent on the rendered pages. It does not name its dispensing pharmacy on its site — confirmed absent on the rendered pages, which refer only to "our partner pharmacies"; the one known publicly surfaced in litigation as Foothills Professional Pharmacy.

Is SkinnyRx legit?

Qualified, with real caveats. SkinnyRx is a genuine operating US entity — Lean Rx, Inc. — using state-licensed pharmacies that compound to individual prescriptions, and it discloses more of its own operating detail than most of this category: refund terms in full, per-lot potency and sterility standards against named USP references, and per-product dosing guides. Against that, the BBB rates it B and does not accredit it, its accreditation status is inconsistent across sources, a February 2026 FDA misbranding warning letter is on the record, and a class action alleges some products were distributed without a genuine medical evaluation.

  • Licensed & accredited: A real operating U.S. entity (Lean Rx, Inc.) using state-licensed pharmacies that compound to individual prescriptions, BBB rates it B (not accredited) and its LegitScript accreditation could not be verified; a Feb 2026 FDA misbranding warning letter is on record — FDA warning letter (fda.gov), Feb 2026.
  • Clinician model: Providers are described as U.S.-licensed and board-certified but none are named, and care is asynchronous in-app messaging with no scheduled appointment — Chimicles (class-action filing), Jul 2026.
  • Medication & pharmacy: Uses state-licensed pharmacies that compound to individual prescriptions, a legal channel; it names no specific pharmacy on its own site — confirmed absent on the rendered pages — and the one identified publicly surfaced in litigation as Foothills Professional Pharmacy — Chimicles (class-action filing), Jul 2026.
  • Watch-outs: A class action challenges the legality/efficacy of its compounded oral tirzepatide and alleges some products shipped without a genuine medical evaluation, and the FDA cited marketing implying approval the products don't have — FDA warning letter (fda.gov) / Chimicles, Feb 2026.

Treatment options

What SkinnyRx actually treats. Pricing lives in the plans table above and in each category review.

  • Weight loss (GLP-1)

    compounded semaglutide and tirzepatide in injectable, sublingual and tablet forms

Pros & cons

Pros

  • Strong Trustpilot rating (~4.7, ~5,000 reviews)
  • No scheduled appointment required; nationwide availability; async in-app care
  • Multiple drug formats (injection, sublingual, tablet) and month-to-month option

Cons

  • Feb 2026 FDA warning letter for misleading marketing + class action over oral tirzepatide

The bottom line

SkinnyRx suits people who want fast, appointment-free access in a choice of formats and who will read the terms — its published refund rules, dosing guides and per-lot testing standards are more detailed than most of this category publishes. Weigh that against a dispensing pharmacy it does not name on its site, an FDA marketing warning letter, a pending class action over its oral tirzepatide, and a complaint record dominated by refunds and cancellations.

What changed & why

This brand's own history — every re-review and methodology recompute, logged. Rankings change when the evidence or the rules change, never for payment. See the site-wide methodology ledger for version history.

  1. Sep 18, 2026Initial score5.59

    SkinnyRx's Operator Trust Score first recorded at 5.59 out of 10 — the earliest score in this log.

Review score changes

The timeline above is this brand's Operator Trust Score. Each review below is scored separately, and keeps its own history.

  • Weight Management / GLP-1 review— last changed Sep 14, 2026See changes

Work at SkinnyRx?

If something here is wrong or out of date, send us a correction request. We read every one and decide what changes — it does not edit the review or move a score.

Sources & how we researched this

Completeness was not recorded for this score · 8 sources cited

Brand site

Regulatory

Reviews

Other

What we couldn't verify

  • Homepage, pricing and eligibility pages at skinnyrx.com are JavaScript-rendered, so a RAW HTML fetch of them yielded only 8 characters (2026-08-10). RESOLVED 2026-08-24: the automated rendered retrieval path reads them normally; the homepage alone returns ~17,900 characters including four published starting prices. This was a limitation of our retrieval, never a property of the brand, and the claims built on it have been corrected.
  • No detailed SkinnyRx privacy/security policy retrievable - data-privacy scored on standard-telehealth assumption.
  • LegitScript accreditation status inconsistent across sources; not confirmed on LegitScript directly.
  • The dispensing pharmacy is not named by SkinnyRx on the pages we reviewed. A pharmacy is named in the pending class-action complaint — an allegation rather than a finding — so we do not restate the name here.
  • Withdrawn — SkinnyRx pricing of $261.75/month for standard-dose compounded semaglutide. SkinnyRx pricing of $261.75/month for standard-dose compounded semaglutide remains WITHDRAWN: its only source returned HTTP 403 (retrieval-failed, not disproved) and no originating source states that figure. CORRECTED 2026-08-24 — the reason previously attached to this withdrawal, which asserted that the brand served no readable content and published no retrievable price at all, was FALSE and an artefact of raw-HTML retrieval. The brand publishes starting prices on its own homepage (compounded semaglutide from $199, semaglutide tablets from $249, tirzepatide from $299). The $261.75 figure is simply not among them, which is why the withdrawal itself stands. Corrected 2026-08-24 against a rendered read of the brand's own site (automated rendering path, terms-gated; skinnyrx.com is the one host the rendered-retrieval spike settled as permitted).
  • Withdrawn — SkinnyRx does not publish its compounding pharmacy names. The claim that SkinnyRx does not publish its compounding pharmacy names is WITHDRAWN as sourced — the 403'd page cannot support it. The absence is instead recorded against the record we do have: no pharmacy is named in the FDA warning letter correspondence or on any retrievable brand page.
  • SkinnyRx support-model detail was WITHDRAWN on 2026-08-10 because its source 403'd and, it was said, nothing was retrievable on the brand's own site. RESOLVED 2026-08-24: the second half of that reason was false — a rendered read returns the brand's published support model in full (unlimited patient-care-team access, no-extra-cost clinician consults through the portal, 24/7 provider access, published phone and email). The factor is now scored on that rendered evidence rather than excluded. The service-quality signal from the BBB complaint record is carried in the observation itself and on the ReviewSource axis, where it belongs.
  • This entry withdrew TWO different claims on one reason, and the rendered read settles them in OPPOSITE directions — so they are now recorded separately. (a) THE REFUND TERMS ARE REINSTATED: "non-refundable once fulfilment has begun" and "bundled subscriptions are non-refundable" are stated verbatim on the brand's own FAQ, so the withdrawal reason — syndicated-newswire sourcing with nothing retrievable from the brand — no longer holds for them. (b) BMI ELIGIBILITY OF 27+ REMAINS WITHDRAWN, and on stronger grounds than before: no BMI threshold of any kind is published anywhere on the rendered site — confirmed absent on the rendered pages searched, not merely unretrieved. A withdrawal is not reversed because its stated reason was wrong; each specific is re-checked on its own. Confirmed on the rendered pages 2026-08-24 (automated rendering path, terms-gated; skinnyrx.com is the one host the rendered-retrieval spike settled as permitted): homepage, /products/semaglutide-injectable and /products/tirzepatide-injectable.
  • Withdrawn — SkinnyRx data-privacy assessment. SkinnyRx data-privacy assessment is WITHDRAWN. The cited quote conceded its own emptiness — "standard US telehealth data-handling context implied but specific privacy terms not surfaced" — which is an inference, not evidence, and it was carrying a scored factor.
  • SkinnyRx "free overnight shipping" was WITHDRAWN on 2026-08-10 because its source was a syndicated newswire placement and our raw fetch of the brand's site could not read it. REINSTATED 2026-08-24: the brand states "Free overnight shipping on all orders" on its own rendered product pages. The withdrawal rested entirely on a retrieval failure rather than on an absence, and the retrieval failure is resolved. Corrected 2026-08-24 against a rendered read of the brand's own site (automated rendering path, terms-gated; skinnyrx.com is the one host the rendered-retrieval spike settled as permitted).
  • Withdrawn — SkinnyRx eligibility criteria (BMI 27+, clinician-determined contraindications). SkinnyRx eligibility criteria (BMI 27+, clinician-determined contraindications) are WITHDRAWN — syndicated newswire sourcing, unconfirmable against the brand.
  • Withdrawn — SkinnyRx titration characterisation ("some users disappointed when prescribed lower starting doses"). The SkinnyRx titration characterisation ("some users disappointed when prescribed lower starting doses") is WITHDRAWN — anonymous user sentiment on a review site, with no verifiable base and no originating record.
  • pricing-transparency-value: this factor was re-encoded as a RETRIEVAL GAP on 2026-08-13, on the premise that the brand's own pages could not be read at all and therefore nothing could be established about what it discloses. THAT PREMISE WAS FALSE — our raw fetcher could not execute the site's JavaScript, which is a limitation of ours and not a property of the brand. SUPERSEDED 2026-08-24: the factor is now scored on rendered evidence read from the brand's own pages (observation 338). Corrected 2026-08-24 against a rendered read of the brand's own site (automated rendering path, terms-gated; skinnyrx.com is the one host the rendered-retrieval spike settled as permitted).
  • transparency-disclosure: this factor was re-encoded as a RETRIEVAL GAP on 2026-08-13, on the premise that the brand's own pages could not be read at all and therefore nothing could be established about what it discloses. THAT PREMISE WAS FALSE — our raw fetcher could not execute the site's JavaScript, which is a limitation of ours and not a property of the brand. SUPERSEDED 2026-08-24: the factor is now scored on rendered evidence read from the brand's own pages (observation 339). Corrected 2026-08-24 against a rendered read of the brand's own site (automated rendering path, terms-gated; skinnyrx.com is the one host the rendered-retrieval spike settled as permitted).
  • support-care-model: this factor was re-encoded as a RETRIEVAL GAP (excluded, re-normalized out of the score) on 2026-08-13, on the premise that the brand's own pages could not be read at all. ⚠️ THAT PREMISE IS FALSE — a rendered read returns the full site. UNLIKE THE OTHER SEVEN, THIS EXCLUSION HAS NOT YET BEEN REVISITED ON RENDERED EVIDENCE and remains open: the factor is still excluded and still re-normalized out of the score, on a reason that no longer holds. It is recorded here rather than left reading as though it were justified. Corrected 2026-08-24 against a rendered read of the brand's own site (automated rendering path, terms-gated; skinnyrx.com is the one host the rendered-retrieval spike settled as permitted).
  • policy-clarity-fairness: this factor was re-encoded as a RETRIEVAL GAP on 2026-08-13, on the premise that the brand's own pages could not be read at all and therefore nothing could be established about what it discloses. THAT PREMISE WAS FALSE — our raw fetcher could not execute the site's JavaScript, which is a limitation of ours and not a property of the brand. SUPERSEDED 2026-08-24: the factor is now scored on rendered evidence read from the brand's own pages (observation 340). Corrected 2026-08-24 against a rendered read of the brand's own site (automated rendering path, terms-gated; skinnyrx.com is the one host the rendered-retrieval spike settled as permitted).
  • data-privacy-security: this factor was re-encoded as a RETRIEVAL GAP on 2026-08-13, on the premise that the brand's own pages could not be read at all and therefore nothing could be established about what it discloses. THAT PREMISE WAS FALSE — our raw fetcher could not execute the site's JavaScript, which is a limitation of ours and not a property of the brand. SUPERSEDED 2026-08-24: the factor is now scored on rendered evidence read from the brand's own pages (observation 344). Corrected 2026-08-24 against a rendered read of the brand's own site (automated rendering path, terms-gated; skinnyrx.com is the one host the rendered-retrieval spike settled as permitted).
  • access-speed: this factor was re-encoded as a RETRIEVAL GAP on 2026-08-13, on the premise that the brand's own pages could not be read at all and therefore nothing could be established about what it discloses. THAT PREMISE WAS FALSE — our raw fetcher could not execute the site's JavaScript, which is a limitation of ours and not a property of the brand. SUPERSEDED 2026-08-24: the factor is now scored on rendered evidence read from the brand's own pages (observation 343). Corrected 2026-08-24 against a rendered read of the brand's own site (automated rendering path, terms-gated; skinnyrx.com is the one host the rendered-retrieval spike settled as permitted).
  • glp1-eligibility-screening: this factor was re-encoded as a RETRIEVAL GAP on 2026-08-13, on the premise that the brand's own pages could not be read at all and therefore nothing could be established about what it discloses. THAT PREMISE WAS FALSE — our raw fetcher could not execute the site's JavaScript, which is a limitation of ours and not a property of the brand. SUPERSEDED 2026-08-24: the factor is now scored on rendered evidence read from the brand's own pages (observation 341). Corrected 2026-08-24 against a rendered read of the brand's own site (automated rendering path, terms-gated; skinnyrx.com is the one host the rendered-retrieval spike settled as permitted).
  • glp1-titration-autonomy: this factor was re-encoded as a RETRIEVAL GAP on 2026-08-13, on the premise that the brand's own pages could not be read at all and therefore nothing could be established about what it discloses. THAT PREMISE WAS FALSE — our raw fetcher could not execute the site's JavaScript, which is a limitation of ours and not a property of the brand. SUPERSEDED 2026-08-24: the factor is now scored on rendered evidence read from the brand's own pages (observation 342). Corrected 2026-08-24 against a rendered read of the brand's own site (automated rendering path, terms-gated; skinnyrx.com is the one host the rendered-retrieval spike settled as permitted).
  • The Trustpilot rating shown on this page is NOT withdrawn, but it cannot be re-verified and it disagrees with itself: the verdict and key takeaways state 4.8 across 5,266 reviews while the pros list states ~4.7 across ~5,000. trustpilot.com is refused on terms — its Terms of Use ban access "through use of automated technologies such as AI agents or screen scrapers" — so we have no route to the figure that we are permitted to use, and cannot settle which of the two is right. Both are published as retrieved on 2026-07-24 and treated as unverifiable from that date forward. This is the fourth brand in the corpus carrying a Trustpilot figure from a host we may not retrieve; the consumer-sentiment observation resting on it is recorded as undermined and has NOT been changed here. (2026-08-25)
Last reviewed Sep 24, 2026View the ledger